All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database

Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis

(2016) André J. Scheen   DIABETES & METABOLISM

EMPA-REG – the “diuretic hypothesis”

(2016) John McMurray   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

(2016) Jason H Y Wu et al.   Lancet Diabetes & Endocrinology

Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study

(2015) S. Sha et al.   DIABETES OBESITY & METABOLISM

Bisphosphonates and Glucose Homeostasis: A Population-Based, Retrospective Cohort Study

(2015) Konstantinos A. Toulis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Understanding EMPA-REG OUTCOME

(2015) Richard E Gilbert et al.   Lancet Diabetes & Endocrinology

Understanding EMPA-REG OUTCOME

(2015) Marcel H A Muskiet et al.   Lancet Diabetes & Endocrinology

Understanding EMPA-REG OUTCOME

(2015) Antonio Ceriello et al.   Lancet Diabetes & Endocrinology

All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large U.K. Primary Care Database

(2013) K. S. Taylor et al.   DIABETES CARE

Adaptation and validation of the Charlson Index for Read/OXMIS coded databases

(2010) Nada F Khan et al.   BMC Family Practice

Negative Controls

(2010) Marc Lipsitch et al.   EPIDEMIOLOGY

Validation of death and suicide recording on the THIN UK primary care database

(2008) Gillian C. Hall   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY